Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7202
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Weppler, A. M. | - |
dc.contributor.author | Da Meda, L. | - |
dc.contributor.author | da Silva, Ines Pires | - |
dc.contributor.author | Xu, W. | - |
dc.contributor.author | Grignani, G. | - |
dc.contributor.author | Menzies, A. M. | - |
dc.contributor.author | Carlino, Matteo S. | - |
dc.contributor.author | Long, G. V. | - |
dc.contributor.author | Lo, S. N. | - |
dc.contributor.author | Nordman, I. | - |
dc.contributor.author | Steer, C. B. | - |
dc.contributor.author | Lyle, M. | - |
dc.contributor.author | Trojaniello, C. | - |
dc.contributor.author | Ascierto, P. A. | - |
dc.contributor.author | Lebbe, C. | - |
dc.contributor.author | Sandhu, S. | - |
dc.date.accessioned | 2023-06-07T01:57:11Z | - |
dc.date.available | 2023-06-07T01:57:11Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | European Journal of Cancer 183:109-118, 2023 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7202 | - |
dc.description.abstract | BACKGROUND: Metastatic Merkel cell carcinoma (mMCC) is highly responsive to immune checkpoint inhibitors (ICIs); however, durability of response after treatment cessation and response to retreatment in the setting of progression is unknown. METHODS: Patients (pts) having mMCC from 10 centres who discontinued ICI treatment for a reason other than progression were studied. RESULTS: Forty patients were included. Median time on treatment was 13.5 months (range 1-35). Thirty-one patients (77.5%) stopped treatment electively while 9 patients (22.5%) stopped due to treatment-related toxicity. After median of 12.3 months from discontinuation, 14 pts (35%) have progressed (PD). Disease progression rate following ICI discontinuation was 26% (8 of 31) in patients who discontinued in complete response (CR), 57% (4 of 7) in patients in partial response and 100% (2 of 2) in those with stable disease. Median progression-free survival (PFS) after treatment cessation was 21 months (95% confidence interval [CI], 18- not reached [NR]), with a third of patients progressing during their first year off treatment. PFS was longer for patients who discontinued ICI electively (median PFS 29 months; 95% CI, 21-NR) compared to those who stopped due to toxicity (median PFS 11 months; 95% CI, 10-NR). ICI was restarted in 8 of 14 pts (57%) with PD, with response rate of 75% (4 CR, 2 partial response, 1 stable disease, 1 PD). CONCLUSIONS: ICI responses in mMCC do not appear durable off treatment, including in patients who achieve a CR, though response to retreatment is promising. Extended duration of treatment needs to be investigated to optimise long-term outcomes. | - |
dc.title | Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.1016/j.ejca.2023.01.016 | - |
dc.subject.keywords | carcinoma, merkel cell | - |
dc.subject.keywords | immune checkpoint inhibitor | - |
dc.subject.keywords | skin neoplasms | - |
dc.identifier.journaltitle | European Journal of Cancer | - |
dc.identifier.department | Oncology | - |
dc.contributor.wslhd | da Silva, Ines Pires | - |
dc.contributor.wslhd | Carlino, Matteo S. | - |
dc.type.studyortrial | Controlled Study | - |
dc.type.studyortrial | Multicentre Study | - |
dc.identifier.pmid | 36842413 | - |
dc.identifier.affiliation | Peter MacCallum Cancer Centre, Melbourne, Australia | - |
dc.identifier.affiliation | Institut du cancer AP-HP. Nord �?? UniversitǸ Paris CitǸ Dermato-Oncology, H��pital Saint Louis, Paris, France | - |
dc.identifier.affiliation | Melanoma Institute of Australia, The University of Sydney, Australia | - |
dc.identifier.affiliation | Faculty of Medicine and Health, The University of Sydney, Australia | - |
dc.identifier.affiliation | Westmead & Blacktown Hospital, Sydney, Australia | - |
dc.identifier.affiliation | Princess Alexandra Hospital, Brisbane, Australia | - |
dc.identifier.affiliation | The University of Queensland, Brisbane, Australia | - |
dc.identifier.affiliation | Candiolo Cancer Institute, FPO e IRCCS, Candiolo (TO), Italy | - |
dc.identifier.affiliation | Royal North Shore and Mater Hospitals, Sydney, Australia | - |
dc.identifier.affiliation | Calvary Mater Newcastle, Waratah, Australia | - |
dc.identifier.affiliation | University of Newcastle, Newcastle, Australia | - |
dc.identifier.affiliation | Border Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury, Australia Cairns Hospital, Cairns, Australia | - |
dc.identifier.affiliation | University of NSW, Rural Clinical Campus, Albury, Australia | - |
dc.identifier.affiliation | Cairns Hospital, Cairns, Australia | - |
dc.identifier.affiliation | James Cook University, Cairns, Australia | - |
dc.identifier.affiliation | Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy | - |
dc.identifier.facility | Blacktown | - |
dc.identifier.facility | Westmead | - |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.